[go: up one dir, main page]

BR112019000790A2 - composições e métodos para tratar hipertensão pulmonar - Google Patents

composições e métodos para tratar hipertensão pulmonar

Info

Publication number
BR112019000790A2
BR112019000790A2 BR112019000790A BR112019000790A BR112019000790A2 BR 112019000790 A2 BR112019000790 A2 BR 112019000790A2 BR 112019000790 A BR112019000790 A BR 112019000790A BR 112019000790 A BR112019000790 A BR 112019000790A BR 112019000790 A2 BR112019000790 A2 BR 112019000790A2
Authority
BR
Brazil
Prior art keywords
gdf
methods
progression
severity
rate
Prior art date
Application number
BR112019000790A
Other languages
English (en)
Other versions
BR112019000790B1 (pt
Inventor
Knopf John
Kumar Ravindra
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of BR112019000790A2 publication Critical patent/BR112019000790A2/pt
Publication of BR112019000790B1 publication Critical patent/BR112019000790B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796Receptors; Cell surface antigens; Cell surface determinants for hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35Corticotropin [ACTH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

em alguns aspectos, a divulgação se refere a antagonistas de gdf/bmp e métodos de usar antagonistas de gdf/bmp para tratar, prevenir, ou reduzir a taxa de progressão e/ou a severidade de hipertensão pulmonar (ph), particularmente tratando, prevenindo ou reduzindo a taxa de progressão e/ou a severidade de uma ou mais complicações associadas a ph. a divulgação também fornece métodos de usar um antagonista de gdf/bmp para tratar, prevenir, ou reduzir a taxa de progressão e/ou a severidade de uma variedade de condições incluindo, mas não limitadas a, remodelagem vascular pulmonar, fibrose pulmonar e hipertrofia ventricular direita. a divulgação fornece ainda métodos de usar um antagonista de gdf/bmp para reduzir a pressão sistólica ventricular direita em um sujeito em necessidade deste.
BR112019000790-3A 2016-07-15 2017-07-14 Uso de uma proteína de fusão para a preparação de um medicamento para tratar hipertensão arterial pulmonar BR112019000790B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662362955P 2016-07-15 2016-07-15
US62/362,955 2016-07-15
US201762453888P 2017-02-02 2017-02-02
US62/453,888 2017-02-02
US201762510403P 2017-05-24 2017-05-24
US62/510,403 2017-05-24
PCT/US2017/042157 WO2018013936A1 (en) 2016-07-15 2017-07-14 Compositions and methods for treating pulmonary hypertension

Publications (2)

Publication Number Publication Date
BR112019000790A2 true BR112019000790A2 (pt) 2019-07-02
BR112019000790B1 BR112019000790B1 (pt) 2024-11-05

Family

ID=

Also Published As

Publication number Publication date
HRP20210694T1 (hr) 2021-09-17
WO2018013936A1 (en) 2018-01-18
MD3496739T2 (ro) 2021-09-30
NO2025008I1 (no) 2025-01-21
NL301313I2 (nl) 2025-04-09
US20210023174A1 (en) 2021-01-28
EP3496739B1 (en) 2021-04-28
DK3496739T3 (da) 2021-05-10
CN116531490A (zh) 2023-08-04
US11065303B2 (en) 2021-07-20
MX2019000618A (es) 2019-11-28
US11219666B2 (en) 2022-01-11
US10695405B2 (en) 2020-06-30
KR20190039716A (ko) 2019-04-15
US20200390860A1 (en) 2020-12-17
EP3928784A1 (en) 2021-12-29
SI3496739T1 (sl) 2021-06-30
JP7391139B2 (ja) 2023-12-04
US10722558B2 (en) 2020-07-28
US20200384080A1 (en) 2020-12-10
RU2748278C2 (ru) 2021-05-21
US20210299216A1 (en) 2021-09-30
US20210299220A1 (en) 2021-09-30
JP2022107775A (ja) 2022-07-22
US10946067B2 (en) 2021-03-16
JP2024009166A (ja) 2024-01-19
US11497794B2 (en) 2022-11-15
AU2017296040A1 (en) 2019-01-31
ES2875905T3 (es) 2021-11-11
KR102512157B1 (ko) 2023-03-21
RS62011B1 (sr) 2021-07-30
MX2021000276A (es) 2021-03-31
JP7220141B2 (ja) 2023-02-09
CN109689085A (zh) 2019-04-26
AU2022283782A1 (en) 2023-02-02
AU2017296040C1 (en) 2023-06-22
US10973880B2 (en) 2021-04-13
FR25C1005I1 (fr) 2025-04-04
PL3496739T3 (pl) 2021-10-11
AU2017296040B2 (en) 2022-12-22
US20230233648A1 (en) 2023-07-27
US20200405814A1 (en) 2020-12-31
HUS2500007I1 (hu) 2025-02-28
EP3496739A1 (en) 2019-06-19
RU2021114098A (ru) 2021-12-14
LT3496739T (lt) 2021-05-25
RU2019104084A3 (pt) 2020-09-24
RU2019104084A (ru) 2020-08-18
US12343378B2 (en) 2025-07-01
CY1124277T1 (el) 2022-07-22
US11622992B2 (en) 2023-04-11
FIC20250004I1 (fi) 2025-01-17
US20200397865A1 (en) 2020-12-24
JP2019521144A (ja) 2019-07-25
MX378869B (es) 2025-03-10
US11318188B2 (en) 2022-05-03
CA3030859A1 (en) 2018-01-18
SMT202100345T1 (it) 2021-07-12
CA3030859C (en) 2024-04-23
US20180221447A1 (en) 2018-08-09
US20180050089A1 (en) 2018-02-22
PT3496739T (pt) 2021-06-21
EP3496739A4 (en) 2020-04-01
HUE054228T2 (hu) 2021-08-30

Similar Documents

Publication Publication Date Title
MX378869B (es) Composiciones y metodos para tratar hipertension pulmonar.
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
EA201891557A1 (ru) Спирогептансалициламиды и родственные соединения как ингибиторы rock
EA201690456A1 (ru) Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
EA201790062A1 (ru) Спироциклогептаны как ингибиторы rock
MD4685B1 (ro) Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
HK1220980A1 (zh) 用於治療龐貝氏症的方法和組合物
MX373965B (es) Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae).
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
PH12017500615B1 (en) Ophthalmic composition comprising cyclosporine and trehalose
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EA202092748A1 (ru) Модуляторы экспрессии apol1
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
GB2535116A (en) Temperature-triggered viscosifier for treatment of a subterranean formation
EA201890212A1 (ru) Новое применение сульфата декстрана
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
EP4491223A3 (en) Compound for use in the treatment of neurogenic orthostatic hypotension
BR112018000814A2 (pt) composição de tensoativo com baixo teor de espuma e métodos de fabricar a mesma
MX389593B (es) Derivados de glucagon.
WO2016023028A3 (en) G protein-coupled receptor kinase 2 inhibitors and methods for use of the same
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease
GB2535952A (en) Viscosifier for treatment of a subterranean formation
MX2022004422A (es) Metodo para el tratamiento del cabello.
MX2023009895A (es) Compuestos y composiciones para tratar la fibrosis.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024015924-4 PROTOCOLO 870240065795 EM 02/08/2024 17:44.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/07/2017, OBSERVADAS AS CONDICOES LEGAIS